Abstract:Background: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis (RA), 40% of patients show poor clinical response, and there is an imperative to unravel the molecular pathways and mechanisms underlying non-response and disease progression. 5-20% of RA individuals do not respond to all current medications including biologic and targeted therapies, which suggests that distinct pathogenic processes underlie multi-drug refractoriness. Objectives: In this brief review we discuss advances from recent studies in precision medicine in rheumatoid arthritis. Methods: Bulk RNA-Sequencing of synovial biopsies from RA individuals combined with histology and deep clinical phenotyping has revealed substantial insights into divergent pathogenic pathways which lead to disease progression and illuminated mechanisms underlying failure to response to specific treatments. Biopsy-driven randomised controlled trials, such as R4RA and the forthcoming STRAP trial, have enabled the development of machine learning predictive models for predicting response to different therapies. Results: In the Pathobiology of Early Arthritis Cohort (PEAC), gene expression analysis showed that individuals could be classified into three gene expression subgroups which correlated with histopathotypes defined by histological markers: pauci-immune fibroid pathotype characterised by fibroblasts and an absence of immune inflammatory cells; diffuse-myeloid pathotype characterised by macrophage influx; and the lympho-myeloid pathotype delineated by the presence of B cells, but typically containing a complex inflammatory infiltrate with ectopic lymphoid structure formation. In the R4RA biopsy-driven randomised controlled trial, patients were randomised to either rituximab or tocilizumab. Comprehensive analysis of synovial biopsies pre/post-treatment identified gene signatures of response associated with pathogenic pathways which could be tracked over time. A group of true refractory patients were identified who had failed anti-TNF prior to the study (it was an entry criterion) and then subsequently failed both trial biologics during the trial. RNA-Seq analysis and digital spatial profiling identified specific cell types including DKK3+ fibroblasts as being associated with the refractory state. We identified machine learning predictive models based on specific gene signatures which were able to predict future response to therapy as well as the refractory state. Conclusions: RNA-sequencing of synovial biopsies has enabled substantial progress in understanding disease endotypes in RA and identifying synovial gene signatures which predict prognosis and future response to treatment.

Advancing precision rheumatology through tissue and blood profiling

Precision medicine in rheumatoid arthritis

Transcript profiling towards personalised medicine in rheumatoid arthritis

Identifying Hidden Drivers Of Heterogeneous Inflammatory Skin Diseases

Immune cell profiling in atherosclerosis: role in research and precision medicine

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue

The importance of functional genomics studies in precision rheumatology

Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness

Molecular portrait of chronic joint diseases: defining endotypes toward personalized medicine

Integration of Phenomics and Transcriptomics Data to Reveal Drivers of Inflammatory Processes in the Skin

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis

Understanding Spondyloarthritis Pathogenesis: The Promise of Single-Cell Profiling

Clinical application of personalized rheumatoid arthritis risk information: translational epidemiology leading to precision medicine

Single-cell analysis in rheumatic and allergic diseases: insights for clinical practice

Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises

Predicting best treatment in rheumatoid arthritis

Leveraging Multi-Tissue, Single-Cell Atlases as Tools to Elucidate Shared Mechanisms of Immune-Mediated Inflammatory Diseases

Tissue gene expression profiles and communication networks inform candidate blood biomarker identification in psoriasis and atopic dermatitis

Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets

Classification of human chronic inflammatory skin disease based on single-cell immune profiling

Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis